SOD1 and amyotrophic lateral sclerosis: While our studies support EphA4 as a possible therapeutic target for patients with ALS with a G93A SOD1 mutation, the clinical effectiveness in human patients with different SOD1 mutations, or sporadic ALS development (sALS) has yet to be assessed.